Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

This double-blind, placebo-controlled trial (n=54) will administer 5-MeO-DMT intramuscular (IM) in varying doses from placebo to 16mg. Half of the cohorts (each with 5 getting 5-MeO, 1 placebo) will receive multiples doses (e.g. 2.5mg followed 3 hours later by 4.5mg). The trial will provide valuable data on the pharmacokinetics and safety of 5-MeO-DMT in humans.

Topic Healthy Subjects Safety
Compound 5-MeO-DMT
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Usona Institute
The Usona Institute was founded by Bill Linton and Malynn Utzinger. Currently, 18 people are associated with it. The institute is a non-profit that sponsors psilocybin research (and is funded by sponsors/philanthropists).

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.